Intra-cellular Therapies Secures Lumateperone Patent Victory, Blocking Generic CAPLYTA® Entry
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Intra-cellular Therapies, Inc. v. Hetero USA, Inc. et al. |
| Case Number | 3:24-cv-08852 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Aug 2024 – Jul 2025 313 days |
| Outcome | Plaintiff Win – Consent Judgment |
| Patents at Issue | |
| Accused Products | Generic lumateperone capsules (ANDA referencing CAPLYTA®) |
Case Overview
The Parties
⚖️ Plaintiff
Biopharmaceutical company focused on CNS disorders, holder of the NDA for CAPLYTA® (lumateperone).
🛡️ Defendant
One of the world’s largest generic pharmaceutical manufacturers, seeking FDA approval for generic lumateperone.
The Patents at Issue
This case hinged on the protection of lumateperone, the active pharmaceutical ingredient in CAPLYTA®:
- • US12070459B2 — Covers lumateperone as the sole active pharmaceutical ingredient.
- • US11980617B2 — Also protects lumateperone formulations and methods of use.
These patents benefit from layered protections including Patent Term Extensions (PTE), Patent Term Adjustments (PTA), and potential pediatric exclusivity.
Protecting your pharmaceutical IP?
Learn how to build robust patent portfolios and navigate Hatch-Waxman litigation.
The Verdict & Legal Analysis
Outcome
The District Court entered a consent judgment in favor of Intra-cellular Therapies. Hetero admitted that the asserted patents are valid and enforceable, and that commercializing its generic lumateperone product would infringe these patents prior to their expiration.
Key Legal Issues
This case was an infringement action under the Hatch-Waxman Act, triggered by Hetero’s ANDA filing referencing CAPLYTA® as the reference listed drug. Hetero’s admissions resolved the dispute, avoiding contested litigation on validity and infringement.
The consent judgment permanently enjoins Hetero from commercializing its generic lumateperone until the expiration of both US12070459B2 and US11980617B2, including any extensions (PTE, PTA, pediatric exclusivity).
Filing a new pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the CNS therapeutic space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications for lumateperone and similar CNS drugs.
- View all related patents in CNS therapeutic areas
- See which companies are most active in CNS drug patents
- Understand claim construction patterns in recent Hatch-Waxman cases
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or drug candidate.
- Input your drug’s chemical structure or therapeutic class
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
CNS drug formulations and API protection
Layered Exclusivity
PTE, PTA, and Pediatric Exclusivity
Settlement Strategy
Consent judgments deter generic entry
✅ Key Takeaways
For Patent Attorneys & Litigators
Robust Hatch-Waxman portfolios with layered exclusivity (PTE, PTA, pediatric) significantly deter generic challenges.
Search related case law →Consent judgments with admitted validity and dismissals of counterclaims provide durable protection, avoiding litigation uncertainty.
Explore settlement strategies →The District of New Jersey remains a strategic venue for innovator pharmaceutical companies enforcing patent rights.
View New Jersey Pharma Cases →For Generic Entrants & R&D Teams
Early FTO analysis is crucial. Assess not only listed Orange Book patents but also continuation filings and potential exclusivities.
Start FTO analysis for my drug →Consider design-around strategies or early invalidity challenges (e.g., IPRs) if facing strong patent protection for APIs or formulations.
Explore IPR Strategies →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.